文献速递类风湿关节炎

Upadacitinib单药治疗甲氨蝶呤初治中重度活动性类风湿关节炎的疗效与安全性(SELECT-EARLY):多中心、多国、随机、双盲、阳性对照试验

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2020-09-08

SELECT-EARLY试验将947例以早期为主、甲氨蝶呤(MTX)初治或暴露有限的类风湿关节炎患者随机分配至Upadacitinib 15 mg、30 mg每日一次或MTX每周7.5-20 mg治疗24周。两种剂量Upadacitinib在第12周ACR50和第24周DAS28-CRP<2.6上均显著优于MTX,影像学无进展比例更高,不良事件频率与MTX相似或略高。

要点

  • Upadacitinib 15 mg和30 mg单药在第12周ACR50及第24周DAS28-CRP<2.6上均显著优于MTX。
  • Upadacitinib两剂量组影像学无进展比例(88%、89%)显著高于MTX组(78%)。
  • 不良事件频率MTX组65%、Upadacitinib 15 mg组64%、30 mg组71%,共报告6例死亡。

核心结论

  • Upadacitinib 15 mg或30 mg单药治疗在临床、影像学和患者报告结局上均显著优于MTX。

研究设计与样本

  • 多中心、多国、随机、双盲、阳性对照试验,947例以早期为主、MTX初治或暴露有限的类风湿关节炎患者按1:1:1随机分配。
  • 患者分别接受Upadacitinib 15 mg每日一次、30 mg每日一次或MTX每周7.5-20 mg,治疗24周。
  • 主要终点为第12周达到ACR50的患者比例和第24周达到DAS28-CRP<2.6的患者比例。

主要发现

  • 第12周ACR50:Upadacitinib 15 mg组52%、30 mg组56%,MTX组28%(P < 0.001)。
  • 第24周DAS28-CRP<2.6:Upadacitinib 15 mg组48%、30 mg组50%,MTX组19%(P < 0.001)。
  • 第24周无影像学进展(改良总Sharp评分≤0):Upadacitinib 15 mg组88%、30 mg组89%,MTX组78%(P < 0.01)。
  • 截至第24周治疗中出现的不良事件频率:MTX组65%、Upadacitinib 15 mg组64%、30 mg组71%。
  • 共报告6例死亡:Upadacitinib 15 mg组2例、30 mg组3例、MTX组1例。

关键数值与推荐

  • 主要终点:第12周ACR50应答比例和第24周DAS28-CRP<2.6比例。
  • 影像学无进展定义为改良总Sharp评分≤0。
  • MTX剂量范围为每周7.5-20 mg。

临床怎么用

  • 对于MTX初治或暴露有限的中重度活动性类风湿关节炎患者,Upadacitinib单药可作为优于MTX的治疗选择。
  • 需关注Upadacitinib 30 mg组不良事件频率略高于15 mg组和MTX组。

局限性

  • 数据仅呈现至第24周。
  • 原文未报告长期安全性或疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The SELECT-EARLY trial was undertaken to study the effect of upadacitinib, an oral, reversible Janus kinase 1-selective inhibitor, as monotherapy in patients with predominantly early rheumatoid arthritis who were naive for or had limited exposure to methotrexate (MTX). METHODS: Patients (n = 947) were randomized 1:1:1 to receive once-daily doses of upadacitinib 15 mg or 30 mg or weekly MTX (7.5-20 mg/week) for 24 weeks. The primary end points were the proportion of patients who met the American College of Rheumatology 50% (ACR50) improvement criteria at week 12, and the proportion in whom a Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) of <2.6 was achieved at week 24. Data are presented through week 24. RESULTS: At baseline, the median disease duration was 0.5 years (range 0-44 years). A total of 840 patients (89%) completed 24 weeks of treatment. The study met both primary end points for upadacitinib 15 mg and 30 mg versus MTX (ACR50 was achieved at week 12 in 52% and 56% of patients, respectively, versus 28% [P < 0.001], and DAS28-CRP <2.6 was achieved at week 24 in 48% and 50% of patients, respectively, versus 19% [P < 0.001]). Statistically significant and clinically meaningful improvements in multiple patient-reported outcomes (PROs) were recorded for both upadacitinib doses versus MTX. Overall, 88% of patients receiving upadacitinib 15 mg and 89% of patients receiving 30 mg, respectively, had no radiographic progression (modified total Sharp score ≤0) compared to 78% of those receiving MTX (P < 0.01). Through week 24, the frequency of treatment-emergent adverse events was similar between the MTX arm (65%) and upadacitinib 15 mg arm (64%), but was slightly higher in the upadacitinib 30 mg arm (71%). Six deaths were reported (2 in the upadacitinib 15 mg arm, 3 in the upadacitinib 30 mg arm, and 1 in the MTX arm). CONCLUSION: Our findings indicate that patients receiving either dose of upadacitinib monotherapy experienced significant improvements in clinical, radiographic, and PROs compared to patients receiving MTX.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. Arthritis Rheumatol. 2020. PMID: 32638504. doi:10.1002/art.41384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。